Shattuck Labs Inc(STTK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.51 | Insider Own | 14.1% | Shs Outstand | 100.7M | Perf Week | 2.14% |
| Market Cap | 0.57B | Forward P/E | - | EPS next Y | -6.83% | Insider Trans | -0.17% | Shs Float | 86.2M | Perf Month | -16.13% |
| Enterprise Value | 0.37B | PEG | - | EPS next Q | -0.11 | Inst Own | 73.89% | Short Float | 12.11% | Perf Quarter | -19.09% |
| Income | -0.05B | P/S | 574.08 | EPS this Y | 30.68% | Inst Trans | 31.72% | Short Ratio | 9.21 | Perf Half Y | -20% |
| Sales | 0.00B | P/B | 2.73 | EPS next 5Y | 5.95% | ROA | -36.88% | Short Interest | 10.44M | Perf YTD | 56.71% |
| Book/sh | 2.1 | P/C | 2.76 | EPS past 3/5Y | 33.69% 4.36% | ROE | -39.21% | 52W High | -31.33% ($8.33) | Perf Year | 193.33% |
| Cash/sh | 2.08 | P/FCF | - | Sales past 3/5Y | 15.32% -36.82% | ROIC | -24.69% | 52W Low | 232.56% ($1.72) | Perf 3Y | 262.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.89% | Gross Margin | -256.5% | Volatility(W/M) | 5.46% 7.32% | Perf 5Y | -70.36% |
| Dividend TTM | - | EV/Sales | 368.45 | Sales Y/Y TTM | -66.63% | Oper. Margin | -5570.6% | ATR (14) | 0.39 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 27.59 | EPS Q/Q | 52.19% | Profit Margin | -5256.8% | RSI (14) | 46.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 27.59 | Sales Q/Q | - | SMA20 | -0.48% ($5.75) | Beta | 1.18 | Target Price | $16 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -9.46% ($6.32) | Rel Volume | 0.6 | Prev Close | $5.8 |
| Employees | 40 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 3.3% - | SMA200 | -5.16% ($6.03) | Avg Volume(3M) | 1.13M | Price | $5.72 |
| IPO | 2020/10/9 | Option/Short | Yes/Yes | Trades | 5633 | Volume | 676,331 | Change | -1.46% |
🧬 Shattuck Labs (STTK) is a clinical-stage biotech company that targets immune disorders and inflammatory diseases. Leveraging its proprietary protein engineering platform, it develops next-generation antibody therapeutics and is exploring the potential for a first-in-class candidate in the inflammatory bowel disease (IBD) space, led by its lead asset. As a research-driven company with no commercialized products yet, pipeline progress is the core driver of its enterprise value.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
STTK has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.7% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $57,408. Peers typically go for $1,217.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -70.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 73.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #209 of 594 in the industry
Based on market cap of $574M.
ACRS#206 Aclaris Therapeutics Inc $587M PER - 
MDXG#207 Mimedx Group Inc $579M PER - 
NGNE#208 Neurogene Inc $577M PER - STTK#209 Shattuck Labs Inc $574M PER - 
DRUG#210 Bright Minds Biosciences Inc $559M PER - 
FAQ
What kind of company is STTK?
STTK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of STTK?
The market cap of STTK is approximately $574M, ranking 3,046 within its sector.
What is the 52-week high and low for STTK?
STTK has recorded a 52-week high of $8.33 and a low of $1.72.
